You are here: Home » PTI Stories » National » News
Business Standard

Zydus receives final nod from USFDA to market Acetazolamide injection

Press Trust of India  |  New Delhi 

Drug firm Wednesday said it has received final nod from the US regulator to market generic

is effective in the control of fluid secretion, for example in some types of glaucoma, and promotion of diuresis in instances of abnormal fluid retention such as cardiac edema, it added.

The company has received final approval from the Food and Drug Administration (USFDA) to market for 500 mg per single-dose vial, said in a filing to BSE.

The product will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

It is a generic version of for injection, it added.

The group now has 262 approvals and has so far filed over 350 abbreviated new drug applications (ANDAs) since the commencement of its filing process, said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, April 17 2019. 15:00 IST